Advancements in ADHD Therapeutics Market Shaping Future Treatments

The ADHD therapeutics market size is expected to be valued at USD 35.17 Billion in 2024 and reach USD 54.34 Billion by 2029, growing at a CAGR of 9.09 % from 2024 to 2029.

Attention-deficit/hyperactivity disorder (ADHD) is marked by an ongoing pattern of inattention or hyperactivity-impulsivity, which interferes with functioning or development. People experiencing ADHD experience symptoms like inattention, hyperactivity, and impulsivity.

Global ADHD Therapeutics Market Report Scope:

Market Size (2029): USD 54.34 Billion
Market Size (2024): USD 35.17 Billion
CAGR (2024 to 2029): 9.09 %
Base Year: 2023
Forecast Period: 2024 to 2029
Segments Analysed: Based on Treatment by Medication, Psychotherapy, Education Type and Region
Geographies Covered: North America, Europe, APAC, Latin America, and Middle East & Africa
Key Market Players Profiled: Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.) are playing a dominant role in the ADHD therapeutics market.

Browse full details of the report @ https://www.marketdataforecast.com/market-reports/attention-deficit-hyperactivity-disorder-therapeutics-market

Key Insights from The Report:

• Based on Treatment by Medication, the stimulants segment captured highest share of the global market in 2023.
• Based on Psychotherapy, the behaviour therapy segment dominated the market in 2023.
• Based on Education Type, the parent management training segment dominated the market in 2023.
• North America dominated the healthcare analytics market in 2023. Europe accounted for second- highest share of the global ADHD therapeutics market in 2023 and on the other hand, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period.
• AMD Global ADHD therapeutics market Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) are dominated the ADHD therapeutics market.

The growing incidence of attention deficit hyperactivity disorder across the world is majorly contributing to the global market growth. The presence of various risk factors like genetics, brain injury, rising alcohol or tobacco usage during pregnancy, cases of premature delivery, and low birth weight cases are all inducing ADHD among children worldwide, which is boosting the demand for ADHD therapeutics, leading to market revenue expansion. According to an article published by the Centers for Disease Control and Prevention (CDC), in February 2022, nearly 6 million children aged 3 to 17 years were diagnosed with ADHD, accounting for 9.8% of the population between 2016 and 2019. According to an article published by PubMed Central in 2022, ADHD affects 5-7.2% of children and 2.5-6.7% of adults worldwide. The increasing prevalence of ADHD and the surge in demand for treatment drugs are primarily driving the market expansion. Various researchers state that ADHD is associated with anxiety, depression, substance abuse, and learning disorders, where the prevalence of these conditions induces ADHD, leading to the growth of market revenue. The growing public awareness regarding mental health due to various government initiatives and public awareness programs are all expected to raise market growth opportunities. Manufacturers' increasing clinical trial investments to develop novel treatment therapeutics for ADHD create opportunities for market players in the coming years. For Instance, according to a study titled "Neurofunctional and behavioral measures associated with Neurofeedback learning in adolescents with ADHD," in May 2020, a large clinical trial with 100 children with ADHD was funded by the Medical Research Council. The growing collaborations and partnerships among the market players and government organizations will expand the market size worldwide.

The expansion of the ADHD therapeutics market is expected to be restrained due to limited relief of the symptoms and the presence of adverse effects like decreased appetite, insomnia, increased anxiety, irritability, stomach ache, and headache. There are higher chances of a rebound effect where the symptoms of ADHD are expected to return after a specific period, which is hampering the market growth. The high costs associated with ADHD drugs and insufficient funding for research activities are estimated to hinder the market size expansion. The need for more awareness across the population, particularly in developing nations, will impede the market growth opportunities.

SEGMENTATION INCLUDED IN THIS REPORT:

Treatment by Medication:
• Stimulants
o Amphetamines
o Methylphenidate
o Dextroamphetamine
o Dexmethylphenidate
• Non-Stimulants
o Atomoxetine
o Bupropion
o Guanfacine

Treatment by Psychotherapy:
• Behaviour Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy

Treatment by Education or Training:
• Parent Management Training
• Social Skills Training
• School-Based Interventions

By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Browse Regional Reports:

North America ADHD Therapeutics Market Research Report - Segmented By Treatment, Medication, Psychotherapy, Education Or Training & By Country (U.S, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/na-attention-deficit-hyperactivity-disorder-therapeutics-market

Europe ADHD Therapeutics Market Research Report - Segmented By Treatment, Medication, Psychotherapy, Education Or Training & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/europe-attention-deficit-hyperactivity-disorder-therapeutics-market

APAC ADHD Therapeutics Market Research Report - Segmented Treatment By Medication, Psychotherapy, Education or Training & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/apac-attention-deficit-hyperactivity-disorder-therapeutics-market

TABLE OF CONTENTS:

1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Treatment By Medication
5.2.1 Introduction
5.2.2 Stimulants
5.2.2.1 Introduction
5.2.2.2 Amphetamines
5.2.2.3 Methylphenidate
5.2.2.4 Dextroamphetamine
5.2.2.5 Dexmethylphenidate
5.2.3 Non-Stimulants
5.2.3.1 Introduction
5.2.3.2 Atomoxetine
5.2.3.3 Bupropion
5.2.3.4 Guanfacine
5.3 Treatment By Psychotherapy
5.3.1 Introduction
5.3.2 Behavior Therapy
5.3.3 Cognitive Behavioral Therapy
5.3.4 Interpersonal Psychotherapy
5.3.5 Family Therapy
5.4 Treatment By Education or Training
5.4.1 5.3.1 Introduction
5.4.2 5.3.2 Parent Management Training
5.4.3 5.3.3 Social Skills Training
5.4.4 5.3.4 School-Based Interventions
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter's Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Shire plc (Ireland)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Neos Therapeutics, Inc. (U.S.)
8.3 Eli Lilly and Company (U.S.)
8.4 Pfizer Inc. (U.S.)
8.5 Alcobra Ltd. (Israel)
8.6 Supernus Pharmaceuticals, Inc. (U.S.)
8.7 Noven Pharmaceuticals, Inc. (U.S.)
8.8 Novartis AG (Switzerland)
8.9 Johnson & Johnson (U.S.)
8.10 Curemark, LLC., (U.S.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
11. Appendix
a) List of Tables
b) List of Figures

Contact Us:
MarketDataForecast
www.marketdataforecast.com
Phone: +1-888-702-9626
Email: sales@marketdataforecast.com
5th Floor, Trendz Pride, Patrika Nagar Rd Number 1, HUDA Techno Enclave, HITEC City, Hyderabad, Telangana 500081, India

About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

This release was published on openPR.